Xenon Pharmaceuticals' XEN1101 shows 'positive' results in Phase 1b study
Xenon Pharmaceuticals announced 'positive' data from its XEN1101 Phase 1b transcranial magnetic stimulation study. XEN1101 is a Kv7 potassium channel opener being developed by Xenon for the treatment of epilepsy. Results will be presented in a podium presentation at the 13th European Congress on Epileptology being held in Vienna. The completed Phase 1b TMS study suggested XEN1101 has an ability to inhibit cortical excitability, an important CNS effect observed with approved anti-epileptic drugs. XEN1101 was well tolerated with all adverse events reported as mild or moderate and reversible. In addition to completing both the Phase 1a pilot and Phase 1b TMS studies, Xenon has now completed enrollment in the XEN1101 Phase 1 clinical trial using a powder-in-capsule formulation, which is evaluating the safety, tolerability and pharmacokinetics of both single ascending doses and multiple ascending doses of XEN1101. A Phase 2 clinical trial in adult focal seizures expected to be initiated in Q4.